InnoCare Pharma Gestion
Gestion contrôle des critères 3/4
InnoCare Pharma's CEO is Jasmine Cui, appointed in Aug 2016, has a tenure of 8.25 years. total yearly compensation is CN¥22.63M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 5.73% of the company’s shares, worth HK$798.37M. The average tenure of the management team and the board of directors is 3.2 years and 9 years respectively.
Informations clés
Jasmine Cui
Directeur général
CN¥22.6m
Rémunération totale
| Pourcentage du salaire du PDG | 20.8% |
| Durée du mandat du directeur général | 8.3yrs |
| Propriété du PDG | 5.7% |
| Durée moyenne d'occupation des postes de direction | 3.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 9yrs |
Mises à jour récentes de la gestion
Recent updates
Is InnoCare Pharma (HKG:9969) A Risky Investment?
Oct 21
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%
Sep 13Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report
Aug 22Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Jun 21Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates
Apr 02Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?
Feb 14Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Oct 06Is InnoCare Pharma (HKG:9969) Using Too Much Debt?
May 11Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?
Apr 11Is InnoCare Pharma (HKG:9969) A Risky Investment?
Jan 25Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt
Sep 05InnoCare Pharma (HKG:9969) Is Using Debt Safely
Apr 30Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥471m |
| Mar 31 2024 | n/a | n/a | -CN¥761m |
| Dec 31 2023 | CN¥23m | CN¥5m | -CN¥631m |
| Sep 30 2023 | n/a | n/a | -CN¥584m |
| Jun 30 2023 | n/a | n/a | -CN¥867m |
| Mar 31 2023 | n/a | n/a | -CN¥781m |
| Dec 31 2022 | CN¥24m | CN¥4m | -CN¥887m |
| Sep 30 2022 | n/a | n/a | -CN¥987m |
| Jun 30 2022 | n/a | n/a | -CN¥296m |
| Mar 31 2022 | n/a | n/a | -CN¥78m |
| Dec 31 2021 | CN¥29m | CN¥3m | -CN¥65m |
| Sep 30 2021 | n/a | n/a | CN¥60m |
| Jun 30 2021 | n/a | n/a | -CN¥266m |
| Mar 31 2021 | n/a | n/a | -CN¥329m |
| Dec 31 2020 | CN¥120m | CN¥1m | -CN¥391m |
| Sep 30 2020 | n/a | n/a | -CN¥2b |
| Jun 30 2020 | n/a | n/a | -CN¥2b |
| Mar 31 2020 | n/a | n/a | -CN¥2b |
| Dec 31 2019 | CN¥17m | CN¥3m | -CN¥2b |
| Sep 30 2019 | n/a | n/a | -CN¥742m |
| Jun 30 2019 | n/a | n/a | -CN¥592m |
| Mar 31 2019 | n/a | n/a | -CN¥571m |
| Dec 31 2018 | CN¥26m | CN¥2m | -CN¥550m |
Rémunération vs marché: Jasmine's total compensation ($USD3.19M) is above average for companies of similar size in the Hong Kong market ($USD496.15K).
Rémunération et revenus: Jasmine's compensation has been consistent with company performance over the past year.
PDG
Jasmine Cui (61 yo)
8.3yrs
Titularisation
CN¥22,626,000
Compensation
Dr. Jisong Cui, Ph.D. also known as Jasmine, has been Co-Founder InnoCare Pharma, Ltd. and serves as Chief Executive Officer of InnoCare Pharma, Ltd. since August 18, 2016 and its Chairwoman since Septembe...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 8.3yrs | CN¥22.63m | 5.73% HK$ 798.4m | |
| VP of Clinical Development & Medical Research and Executive Director | no data | CN¥4.06m | 8.21% HK$ 1.1b | |
| Chief Financial Officer | less than a year | pas de données | pas de données | |
| Chief Operating Officer | 3.3yrs | pas de données | pas de données | |
| Accounting Supervisor | no data | pas de données | pas de données | |
| Chief Technology Officer | 5.1yrs | pas de données | 0.0071% HK$ 988.3k | |
| General Counsel | 3.2yrs | pas de données | pas de données | |
| VP & Head of Biology | 3.2yrs | pas de données | pas de données | |
| Chief Commercial Officer | less than a year | pas de données | pas de données | |
| Secretary of the Board | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board in Sales & Marketing | no data | pas de données | pas de données |
3.2yrs
Durée moyenne de l'emploi
52.5yo
Âge moyen
Gestion expérimentée: 9969's management team is considered experienced (3.2 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 9yrs | CN¥22.63m | 5.73% HK$ 798.4m | |
| VP of Clinical Development & Medical Research and Executive Director | 9yrs | CN¥4.06m | 8.21% HK$ 1.1b | |
| Member of Scientific Advisory Board in Sales & Marketing | no data | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Non-Executive Director & President of Scientific Advisory Board | 9yrs | pas de données | 0.18% HK$ 24.5m | |
| Member of Scientific Advisory Board | 9yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Non-Executive Director | 3.7yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 4.7yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 1.1yrs | pas de données | pas de données |
9.0yrs
Durée moyenne de l'emploi
55.5yo
Âge moyen
Conseil d'administration expérimenté: 9969's board of directors are considered experienced (9 years average tenure).